<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359138</url>
  </required_header>
  <id_info>
    <org_study_id>P04441</org_study_id>
    <nct_id>NCT00359138</nct_id>
  </id_info>
  <brief_title>The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)</brief_title>
  <official_title>A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single
      center study in subjects with positive histamine skin prick test and a positive
      RadioAllergoSorbent Test (RAST) (class &gt; 2) to one of the tested standardized allergenic
      extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens.
      Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily,
      or placebo once daily for 8 days of treatment followed by 11 days of skin testing after
      discontinuation of the antihistamine treatment phase. The duration of the suppressive effects
      of desloratadine on cutaneous allergen-induced wheal and flare responses after
      discontinuation of a one-week treatment will be established.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment</measure>
    <time_frame>Starting at Day 8</time_frame>
    <description>The number of days after treatment discontinuation until a measurable wheal and flare response.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Desloratadine 5 mg tablet + Levocetirizine placebo capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desloratadine placebo tablet + Levocetirizine 5 mg capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desloratadine placebo tablet + Levocetirizine placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>5 mg tablet once daily</description>
    <arm_group_label>Desloratadine 5 mg tablet + Levocetirizine placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levocetirizine</intervention_name>
    <description>5 mg capsule once daily</description>
    <arm_group_label>Desloratadine placebo tablet + Levocetirizine 5 mg capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine placebo tablet</intervention_name>
    <description>once daily</description>
    <arm_group_label>Desloratadine placebo tablet + Levocetirizine 5 mg capsule</arm_group_label>
    <arm_group_label>Desloratadine placebo tablet + Levocetirizine placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine placebo capsule</intervention_name>
    <description>once daily</description>
    <arm_group_label>Desloratadine 5 mg tablet + Levocetirizine placebo capsule</arm_group_label>
    <arm_group_label>Desloratadine placebo tablet + Levocetirizine placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18 years of age or older, of either sex.

          -  Subjects must have at least a history of positive skin testing to the allergens of
             tree pollen, grass pollen, house dust mite, or cat dander.

          -  Non symptomatic volunteers allergic of different pollen they must be included out of
             the specific pollinic season.

          -  Subjects must demonstrate their willingness to participate in the study and comply
             with its procedures by signing a written informed consent.

          -  Subjects must understand and be able to adhere to visit schedules

          -  Subjects must be in general good health.

          -  Women of child-bearing potential must have a negative pregnancy test at Day -1 and
             must use an accepted method of contraception during the entire duration of the study.

        Exclusion Criteria:

          -  Subjects who have persistent asthma.

          -  Subjects who have chronic urticaria or atopic dermatosis.

          -  Subjects who have received any treatment listed below more recently than the indicated
             washout period prior to Randomization, or who must continue to receive treatment as
             listed below.

        Medications Prohibited During the Trial and Washout Period Prior to Visit 1

          -  Corticosteroids

               -  Intramuscular or intra-articular, 1 month

               -  Oral, inhaled, intravenous, rectal, intranasal, or ocular, 7 days

               -  High-potency dermatological, 7 days

          -  Cromolyn/Lodoxamide/Nedocromil

               -  Intranasal, ocular, inhaled, or oral, 2 days

          -  Antihistamines

               -  Long-acting prescription (eg, levocetirizine, fexofenadine, and desloratadine),
                  15 days

               -  Short-acting (eg, chlorpheniramine, brompheniramine including over-the-counter
                  [OTC] forms, hydroxyzine), 15 days

               -  Ocular (eg, levocabastine), 15 days

          -  Leukotriene inhibitors (eg, montelukast), 7 days

          -  Systemic antibiotics, 14 days (the washout refers to antibiotics used to treat an
             upper or lower respiratory tract infection)

          -  Immunotherapy (desensitization), 1 year

          -  Decongestants

               -  oral, 2 days

               -  local, 2 days

          -  Ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs; eg, Toradol), 5 days

          -  Investigational medications, 30 days

          -  Tricyclic antidepressants (eg, amitriptyline, clomipramine, doxepin, imipramine,
             trimipramine, amoxapine, desipramine, nortriptyline, protriptyline), 30 days

          -  Tetracyclic antidepressants (eg, maprotiline, mirtazapine), 30 days

               -  Subjects with a history of hypersensitivity to desloratadine, to levocetirizine,
                  or any of their excipients.

               -  Women who are breast-feeding, pregnant, or intend to become pregnant.

               -  Subjects with any clinically significant condition or situation, other than the
                  condition being studied, that, in the opinion of the investigator, would
                  interfere with the study evaluations or optimal participation in the study.

               -  Subjects who have used any investigational drugs within 30 days of randomization.

               -  Subjects working between 11 PM and 8 AM (night shift).

               -  Subjects who have skin/color pigmentation incompatible with accurate measurements
                  of flare reaction.

               -  Subjects with cutaneous hyperactivity: negative prick test control &gt;3 mm.

               -  Subjects who are participating in any other clinical study.

               -  Subjects who are part of the staff personnel directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2006</study_first_submitted>
  <study_first_submitted_qc>July 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <results_first_submitted>May 27, 2010</results_first_submitted>
  <results_first_submitted_qc>October 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2010</results_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histamine H1 Antagonists</keyword>
  <keyword>Anti-Allergic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="P2">
          <title>Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="P3">
          <title>Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="B2">
          <title>Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="B3">
          <title>Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.42" spread="4.91"/>
                    <measurement group_id="B2" value="28.33" spread="8.69"/>
                    <measurement group_id="B3" value="28.83" spread="11.55"/>
                    <measurement group_id="B4" value="26.86" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment</title>
        <description>The number of days after treatment discontinuation until a measurable wheal and flare response.</description>
        <time_frame>Starting at Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule</title>
            <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule</title>
            <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
          </group>
          <group group_id="O3">
            <title>Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule</title>
            <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment</title>
          <description>The number of days after treatment discontinuation until a measurable wheal and flare response.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.65" lower_limit="0.4613" upper_limit="0.9400"/>
                    <measurement group_id="O2" value="4" spread="1.60"/>
                    <measurement group_id="O3" value="NA">Results are based on the individual active group relative to placebo.
Not applicable for placebo relative to placebo</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="E2">
          <title>Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
        <group group_id="E3">
          <title>Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule</title>
          <description>Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

